This specialized case study explores Kymanox’s approach to combination product strategy and Design History File (DHF) optimization through risk-based verification and platform development methodologies. Our team of Subject Matter Experts (SMEs) collaborated closely with pharmaceutical stakeholders to implement measurable improvements across device development processes, clinical readiness pathways, regulatory requirement interpretation, and DHF documentation for organizations transitioning from drug-only to combination product portfolios.
CHALLENGE
SOLUTION
RESULTS
- Established drug-focused pharmaceutical organization required strategic guidance to successfully branch into combination product development and commercialization.
- DHF optimization essential ensuring efficient device development documentation meeting regulatory expectations without redundant activities.
- Clear pathway to clinical readiness needed addressing regulatory requirements for clinical study execution with comprehensive response to 10+ specific technical inquiries.
- Risk-based approach required to streamline verification requirements while maintaining regulatory compliance and patient safety throughout development process.
- Conducted comprehensive analysis identifying key scenarios where specific verification requirements could be strategically reduced utilizing risk-based approach aligned with regulatory guidance.
- Developed platform approach to device development and DHF documentation. This enabled efficient reuse of design elements, verification activities, and technical documentation across product variants.
- Provided detailed educational content on combination product regulatory landscape, FDA and international requirements, and device development best practices.
- Evaluated bridging options leveraging existing device platforms, predicate devices, and prior development work to accelerate clinical readiness timeline.
- Delivered comprehensive, detailed answers to client’s 10+ specific technical and regulatory inquiries supporting informed decision-making.
- Delivered comprehensive project deliverable including educational regulatory background, strategic bridging options, and detailed technical answers addressing all specific client questions.
- Enabled efficient transition from drug-focused organization to combination product development through optimized DHF processes and risk-based verification approach.
- Established scalable platform development framework supporting future combination product pipeline and reducing development timelines for subsequent products.
- Provided strategic foundation for clinical study preparation ensuring regulatory compliance while optimizing resource allocation and accelerating time-to-clinic.